Amgen Inc. (AMGN) Oppenheimer 34th Annual Healthcare Life Sciences Conference (Transcript)

It is entirely fair to state that weight loss treatments have massive transformational power. US FDA approval of weight loss medicines could help shrink millions of waistlines.

Amgen is the latest big pharma to join the gold rush to treat obesity. Its candidate is distinct from the medicines by Eli Lilly and Novo Nordisk.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Amgen (AMGN). But which of these two stocks offers value investors a bett...

Jared Holz, Mizuho, joins 'Closing Bell Overtime' to talk Amgen's obesity drug trial results.

Amgen (AMGN) beats fourth-quarter estimates for earnings and sales. Horizon's products add $954 million in sales in the quarter.

Amgen Inc. (AMGN) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Str...

Amgen (AMGN) came out with quarterly earnings of $4.71 per share, beating the Zacks Consensus Estimate of $4.66 per share. This compares to earnings of $4.09 per share a year ago.

Amgen Inc. on Tuesday reported fourth-quarter profits and sales that topped analysts' expectations even as revenues dropped for one of its top sellers, the rheumatoid-arthritis drug Enbrel.

Amgen stock dipped late Tuesday after the company beat fourth-quarter sales expectations, noting nine products hit records.

Amgen on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of rare disease drugmaker Horizon Th...

The popularity of a new generation of weight-loss medicines is inspiring a growing number of drugmakers to pursue paths emulating Eli Lilly's highly-effective Zepbound, but Amgen is taking a unique...

While the Nasdaq exchange and S&P 500 grabbed the headlines because of the massive run-up by the so-called Magnificent 7 stocks, the Dow Jones Industrial Average plodded on with its Dow stocks to b...

Animal and early-stage human trial data for Amgen's experimental obesity drug published in a medical journal showed that it promoted significant weight loss with an acceptable safety profile, the c...